Understanding Novel Therapeutic Agents for Multiple Myeloma

multiple myeloma, stem cell transplantation, antineoplastic protocols
CJON 2003, 7(5), 521-528. DOI: 10.1188/03.CJON.521-528

Multiple myeloma, a B cell malignancy of the plasma cells, remains incurable. Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. New therapeutic agents have shown promising clinical use in patients with relapsed or refractory multiple myeloma. This article discusses the therapeutic applications of these novel agents with a focus on immunomodulatory drugs, proteasome inhibitors, and arsenic compounds.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.